Sanofi (SANp)

Get an in-depth profile of Sanofi, including a general overview of the company's business and key management, as well as employee data and location and contact information.

99.62 +1.55 (+1.59%)

16:47:23 Delayed Data EUR Disclaimer

Sanofi Company Profile

Industry: Pharmaceuticals
Sector: Healthcare
Employees: 95442
Equity Type: ORD

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Contact Information

Address: Paris,75017 France
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 43 03
Web: https://www.sanofi.com

Top Executives

Name	Age	Since	Title
Fabienne Lecorvaisier	59	2013	Independent Director
Jean-François Dehecq	81	1982	Honorary Chairman
Patrick Kron	68	2014	Independent Director
Paul Hudson	54	2019	CEO & Director
Serge Weinberg	70	2009	Chairman of the Board
Gilles Schnepp	63	2021	Independent Director
Diane D. Souza	70	2016	Independent Director
Rachel Duan	52	2020	Independent Director
Lise Kingo	61	2020	Independent Director
Ceng-Yann Tran	57	2021	Employee Representative Director
Thomas C. Sudhof	67	2016	Independent Director
Emile Voest	0	2022	Independent Director
Christophe Babule	57	2019	Director
Carole Ferrand	52	2022	Independent Director
Wolfgang Laux	54	2021	Employee Representative Director
Barbara Lavernos	54	2021	Director
Antoine Yver	64	2022	Independent Director
Frederic Oudea	59	2022	Non-Voting Member of the Board

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.